In the present study we describe the synthesis and some pharmacological properties of eight new analogues of bradykinin (BK). 
INTRODUCTION
Over the past two decades it has become clear that various kinins and their receptors are involved in numerous physiological functions. From the standpoint of therapeutic intervention, the well known pro-inflammatory effects of bradykinin (BK) and its metabolites mediated through B 1 and B 2 receptors (Fein et al., 1997; Ahluwalia & Perretti, 1999; McLean et al., 2000; Couture et al., 2001; Marceau & Regoli, 2004) are prominent among those processes. Some severe disease conditions, such as chronic in-flammatory pain, sepsis, edema, head trauma and asthma, have their basis in the inflammatory response. In this situation, development of the B 1 and B 2 receptor antagonists could provide novel therapeutics. The therapeutic targets have been the subject of intense research for some time now (Fujie et al., 1993; Perkins et al., 1993; Sharma, 1993; Fink, 1998; Stewart et al., 1999; Heitsch, 2003; Howl & Payne, 2003; Zausinger, 2003) and a limited number of published human clinical studies have been conducted concerning pain, asthma, rhinitis and septic shock Proud et al., 1995; Akbary et al., 1996; Fein et al., 1997; Turner et al., 2001) showing some level of efficacy with BK antagonists. A key question that awaits appropriate clinical trials is to what extent the results from animal studies translate to humans. The therapeutic areas currently of most interest are driven by medical needs and include pain, cardiovascular function, asthma and cancer.
The B 2 receptor had not been clearly defined until 1985 when the first generation of antagonists based on ]BK was produced (Vavrek & Stewart, 1985) . In those early compounds (e.g. [Thi 5, 8 , dPhe 7 ]BK), the transition to partial agonist or an antagonist was caused by a structural change introduced by a non-natural amino-acid residue (d-Phe). The added rigidity at this position in subsequent peptide antagonists such as icatibant (Hoe 140, [dArg 0 ,Hyp 3 ,Thi 5 ,d-Tic 7 ,Oic 8 ]BK) (Hock et al., 1991) and NPC17731 ([d-Arg 0 ,Hyp 3 ,d-HypE(transpropyl) 7 , Oic 8 ]BK) (Trifilieff et al., 1993) showed that the spatial orientation of the C-terminal region of the peptide molecule was critical for antagonism. Icatibant exhibits a high affinity for the B 2 receptor, no residual agonist activity in most mammalian species and an impressive resistance to peptidases. The combination of these properties contributes to its prolonged action (several hours) in animal models.
In our laboratory we have explored several structural factors that might affect the antagonistic properties of BK analogues (Lammek, 1994; Prahl et al., 1997a; Labudda-Dawidowska et al., 2005; Labudda et al., 2006) . We confirmed that the antagonistic activity at the B 2 receptor might be attributed to peptides having at position 7 a suitable achiral, non-aromatic, conformationally constrained amino acid, e.g. 1-aminocyclohexane-1-carboxylic acid (Acc). We described BK analogues modified by introduction of an ethylene-bridged dipeptide unit, -&d-Phe-(&)d-Phe-, in positions 6-7 or 7-8 and Acc or 1-aminocyclo-pentane-1-carboxylic acid (Apc) residues in positions 6, 7 or 8 of the known [dArg 0 ,Hyp 3 ,Thi 5,8 ,d-Phe 7 ]BK antagonist (Stewart's antagonist) . We demonstrated the importance of appropriate localization in the molecule of the modification used for ensuring the antagonistic activity. Our results, obtained for analogues modified at position 7 of the previously synthesized antagonist with 1-naphthyl-d-alanine (d-1-Nal) or 2-naphthyl-d-alanine (d-2-Nal) residues (the first one exhibited low potency, the latter was distinctly effective) highlighted the importance of conformation of the C-terminal part of the peptide for its antagonistic properties. It should be emphasized that the great difference observed in the activities is due to a minor change in the structure of the analogues; they differ only in the connection of the naphthalene ring to the backbone of the molecule -through either position 1 or 2 (Prahl et al., 1997b) . We reported that acylation of the Nterminus of B 2 antagonists with various bulky acyl groups (e.g. 1-adamantaneacetyl, 1-adamantanecarbonyl, 4-tert-butylbenzoyl, palmitoyl, etc.) improved the antagonistic potency in rat blood pressure assay (up to 33-fold) (Lammek, 1994) .
Bearing all this in mind, we decided to check how the replacement of amino-acid residues at po- (Schachter et al., 1987) with l-pipecolic acid (l-Pip) residue (which may be considered as homoproline, see Fig. 1 ) would influence pharmacological properties of the resulting analogues (I and III). l-Pip should reduce the flexibility of the peptide backbone similarly to the Acc modification. Like the Acc residue, the l-Pip ring also consists of six atoms, but it has a nitrogen atom in its structure. The next two peptides (V and VII) were designed by substitution of position 7 of the Stewart's antagonist with other proline derivatives, either its structural isomer, l-β 2 -isoproline (l-β 2 -iPro), or its homologue, l-β 3 -homoproline (l-β 3 -hPro), see Fig. 1 , the structures differing only slightly. It is worth emphasizing that this position in the BK molecule is occupied by a Pro residue. The aforementioned four analogues (I, III, V and VII) were also synthesized in the N-acylated form using 1-adamantaneacetic acid (Aaa) (II, IV, VI and VIII).
MATERIALS AND METHODS
Experimental. High-performance liquid chromatography (HPLC) was carried out on a Waters 
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(analytical and semi-preparative) chromatograph equipped with a UV detector (λ = 226 nm). The purity of the peptides was determined on a Hypersil C 18 column (5 μm, 100 Å; 250 × 4.6 mm). The following solvent systems were used: [A] 0.1% aqueous trifluoroacetic acid (TFA), [B] 80% acetonitrile in aqueous 0.1% TFA (v/v) . A linear gradient from 20 to 80% of [B] in 30 min was applied for peptides at a flow rate of 1 mL/min. Semi-preparative HPLC was carried out using a Waters C 18 column (15 μm, 100 Å; 7.8 × 300 mm) in a linear gradient from 15 to 45% of [B] in 60 min at a flow rate of 2.5 mL/ min. The FAB/MS of the peptides were recorded on a TRIO-3 mass spectrometer at 7 keV with argon as the bombarding gas and on a Bruker BIFLEX III MALDI TOF mass spectrometer (ionization: 337 nm nitrogen laser).
Peptide synthesis. The peptides were synthesized by the solid-phase method using the Fmoc strategy and starting from Fmoc-Arg(Pbf) Wang resin (Wang, 1973 ) (GL Biochem Shanghai Ltd., 1% DVB, 100-200 mesh, 0.4 mmol/g). Fmoc was removed by 20% piperidine in DMF. A 3-fold excess of respective Fmoc-amino acids was activated in situ using TBTU (1 eq) / HOBt (1 eq) in a mixture of DMF/NMP (1:1, v/v) containing 1% Triton, and coupling reactions were base-catalyzed with NMM (2 eq). The amino acid side-chain protecting groups were Bu t for Hyp and Ser and Pbf for Arg and dArg. All the Fmoc-protected amino acids were commercially available (NovaBiochem, Bad Soden, Germany). l-β 2 -iPro was prepared from 4-hydroxyproline using a known procedure (Klein et al., 1997; Cardillo et al., 2000) . For the synthesis of l-β 3 -hPro we used modified version of the procedure described by Cardillo et al. (2002) . Aaa was coupled in the final coupling step (peptide II, IV, VI, VIII) using the same procedure as that for the Fmocamino acids. Cleavage of the peptides from the resin with side-chain deprotection was performed by treatment with TFA/H 2 O/TIS (95.5:2.5:2.5, by vol.) for 4 h. The total volume of the TFA filtrate was evaporated in vacuo to about 1 mL. The peptides were precipitated with cold diethyl ether and filtered through a Schott funnel. All the peptides were purified by semi-preparative HPLC.
The physicochemical properties of peptides I-VIII are presented in Table 1 .
Effect of BK analogues on rat blood pressure. The antagonistic potency of the BK analogues was assessed by their ability to inhibit the vasodepressor response to exogenous BK in conscious rats. Male Wistar rats (n = 89; 318-458 g) were maintained on a regular chow diet and tap water at ambient temperature (22±1°C). The assay of the antagonistic potency of the BK analogues was the same as described in detail in references (Labudda-Dawidowska et al., 2005; Labudda et al., 2006; 2007) with minor modifications.
The rats had two arteries cannulated and all catheters were exteriorized subcutaneously at the back of the neck. A Y-type connector was mounted to the carotid artery line. Following a 40-44 h recovery, mean arterial pressure (MAP) and heart rate (HR) were monitored through a Gould-Statham P23-ID pressure transducer (Gould, Cleveland, OH, USA) connected to the iliac catheter. Angiotensin converting enzyme (kininase II) inhibitor, enalapril (Merck Sharp and Dohme Research Lab., Rahway, NJ, USA; 1 mg/kg), was injected into the iliac artery to stabilize the blood pressure. To provide homogeneity of further assay, rats with MAP within the range of 85-135 mmHg and HR 270-350 beats/min were arbitrarily enrolled to the study. Two doses of BK (bradykinin acetate salt; Sigma, USA), 125 ng or 250 ng per animal, dissolved in 5% d-glucose at a concentration of 1.25 μg/mL, were randomly injected four or five times, every 4 to 5 min, into one branch of the carotid catheter. The rats which exhibited vasodepressor response to 250 ng BK (ΔMAP) within the range of 20 to 45 mm Hg were enrolled to the study. In accordance with the previous study (Labudda et al., 2007) , those rats which displayed the vasodepressor response to 125 ng BK higher than 82% of that evoked by 250 ng BK were not included in the blood pressure test. The BK dose of 250 ng was used as a standard in further assay.
The BK analogues dissolved in 5% d-glucose were infused (constant infusion rate 80 μL/min) to the other branch of the carotid catheter. The testing was initiated with the 10-min infusion at a concentration of 1 μg/mL (this gave a dose of 0.08 μg/min per rat). During this infusion, the 250 ng dose of BK was injected twice: at 270 s and at 570 s. The concentration of the infused BK antagonist was then increased to 4, 16, 64, 256, 1024 μg/mL and, if necessary, up to 2048 or 3580 μg/mL, to give the doses 28, 5.12, 20.48, 81.92, 163.84 and 286 .40 μg/ min per rat, respectively. The BK analogue infusion at concentrations of 1024 μg/mL and higher was limited to 5 min and BK was injected only once by the end of the infusions. As soon as the vasodepressor response to BK was lower than 10% of the standard response, the procedure was completed. The percent inhibition of the vasodepressor response to 250 ng BK by the tested BK antagonist was plotted against the logarithm of the dose. From these dose response curves, effective doses ED 20 , ED 50 and ED 90 , were determined representing doses of the BK antagonist (μg/min) that inhibit vasodepressor response to the agonist (250 ng of BK) by 20, 50 and 90%, respectively. The results are reported as mean values ± S.E.M.
The in vitro rat uterotonic test. All the analogues were evaluated in the in vitro rat uterotonic assay using a modified Holton's method (Holton, 1948) in Munsick solution (Munsick, 1960 ) on a strip of rat uterus. Wistar rats in estrus induced by injection of estrogen 48 h before the experiments were used. BK was used as a standard over a concentration range of 10 pM to 10 nM. Cumulative dose-response curves were constructed both in the absence and presence of various doses of the analogues, i.e. doses of BK were added successively to the organ bath in doubled concentrations and at 1-min intervals, without the fluid being changed, until the maximum contraction was obtained. The height of a single isometric contraction in response to different doses of BK was measured. The antagonist was applied to the organ bath 1 min prior to the cumulative dosing of BK. The antagonistic activity was expressed as pA 2 , i.e. negative common logarithm of the analogue concentration which shifted the dose-response curve of BK by a factor of two (comparison of the linear portions of the dose-response curves). Each analogue was tested on uteri taken from 3-5 rats. As far as the agonistic activity of the analogues is concerned, it was calculated by comparing the threshold doses of cumulative dose-response curves of the analogue and that of standard BK. The activity of BK was taken as 100%.
RESULTS
The eight new BK analogues (I-VIII) were synthesized in excellent purity (higher than 98% according to analytical HPLC) and satisfactory yield for biological testing. Pharmacological properties of the new compounds and Stewart's antagonist (Schachter et al., 1987) used as a positive control are summarized in Table 2 . The potency was assayed in the rat uterus test and blood pressure test using conscious rats as described in the Materials and Methods section.
Basal hemodynamic characteristics of the tested rats are typical of unrestrained rats at daytime. The whole population appeared homogeneous, since no significant differences among selected rat subsets were found. Prior to the administration of BK, MAP averaged 113.68 ± 1.59 mm Hg (ranging from 94 to 135 mm Hg) and HR was 311.30 ± 2.70 beats/min (ranging from 278 to 345 beats/min). BK evoked a significant vasodepressor response (19.45 ± 1.10 and 26.42 ± 1.36 mm Hg, for doses 125 and 250 ng, respectively). The relatively low HR recorded during experiments confirmed good recovery of the rats from the surgical procedures and also good acclimatization to the experimental conditions. No signs of discomfort were noticed during the test.
Four out of eight tested BK analogues: III, V, VI and VII elicited a direct vasodepressor response at low doses. Although endogenous BK is not the major vasodilatory contributor that takes part in the regulation of arterial pressure, the evoked decrease in MAP may suggest some BK agonistic potency. On the other hand, all of the aforementioned BK analogues inhibited the vasodepressor responses of exogenous BK at high doses.
It is of interest that some of the tested BK analogues (V and VI) evoked tachyphylaxis to BK: when BK was administered at intervals shorter than 5 min, the second vasodepressor response was regularly lower. From a practical point of view, the development of tachyphylaxis may disturb the antagonistic potency assay. Unlike in our previous tests (Labudda-Dawidowska et al., 2005; Labudda et al., 2007) , we decided to take the response to the initial dose of BK during infusion of the BK analogues for the data analysis. The possibility that a BK analogue may induce tachyphylaxis to BK indicates that one should evaluate the rough data with caution. Eventually, in bioassays consisting of repetitive BK dosage during BK analogue infusions, higher antagonistic potency of BK analogues may be estimated than that calculated from an assay based on a less extensive dosage pattern.
The potencies of our analogues in the rat blood pressure test are summarized in Table 2 . Compound I possessed high antagonistic potency, comparable to that of the Stewart's peptide. Its acylated form was, however, highly potent only at low doses (20% inhibition of the effect of BK by 1.3 μg/min). Data for analogue III, which was designed by replacement of Thi at position 8 of the model peptide by the l-Pip residue, showed that this modification resulted in a potent antagonist of BK in the test. At low doses (ED 20 ), its activity was approximately 4 times higher than that of the Stewart's peptide and it was about 5 times more potent when inhibiting New bradykinin B 2 receptor antagonists the effect of BK by 90%. Acylation of compound III with Aaa decreased the antagonistic activity about 2-fold. Notwithstanding, peptide IV was still more potent than the reference one. Analogues V and VI were weak B 2 agonists at low doses. They showed, however, a weak antagonism of BK at high doses. Compound VIII possessed weak antagonistic properties as compared to those of the model peptide. Unlike the other tested pairs of analogues, the nonacylated counterpart VII showed only negligible antagonistic activity.
In the in vitro uterus assay compounds I, II, V, VI, VII and VIII displayed agonistic potency much lower than that of BK. The dose-response curves for the analogues were parallel to that for bradykinin. The analogues showed no antagonistic activity. Peptide III and its acylated counterpart IV exhibited rather potent antagonism, comparable or even higher, respectively, than that of the Stewart's peptide.
DISCUSSION
In the present study we continue our previous investigations of BK analogues to find structural requirements which result in high B 2 antagonistic activity. Recently we reported that the Acc residue could be accepted in positions 7 and 8 of the model B 2 antagonist molecule -the Stewart's antagonist. We found that the Acc 8 modification resulted in an increase of B 2 antagonistic potency in blood pressure test and preservation of the antagonistic properties in the rat uterus test. As a result of this substitution in position 7, we obtained analogues inactive in the rat uterus test but showing BK antagonistic potency in the blood pressure test. Nevertheless, their activity was lower than that of the model peptide. In the present work we substituted positions 7 or 8 of the same model peptide with the l-Pip residue. Compared to Acc, the ring of l-pipecolic acid also consists of six atoms, but has a nitrogen atom in its structure. Previous theoretical and experimental studies have shown that 1-aminocycloalkane-1-carboxylic acids impart considerable stereochemical rigidity to peptide backbones, which are constrained to adopt conformations in the 3 10 /α-helical regions of the φ and ψ spaces (Paul et al., 1986; Toniolo et al., 1989; Toniolo & Benedetti, 1994; Paradisi et al., 1995; Sikorska & Rodziewicz-Motowidło, 2008) . Similar to Acc modifications, l-Pip changed the character of the relevant fragment of the molecule from aromatic to aliphatic and reduced its conformational freedom. From the presented results it is clear that replacement of the residue at position 8 by l-Pip, similar to Acc 8 modification, is advantageous for B 2 antagonistic potency. The resulting analogue retains the antagonistic properties also in the utero- tonic test. A similar though less distinct effect was noticed following l-Pip 7 substitution. Analogue I is another example of B 2 antagonist with suitable nonaromatic conformationally constrained amino-acid residue at this position that supports our previous results (Prahl et al., 1997a; 1997b; Derdowska et al., 2001; Labudda-Dawidowska et al., 2005; Labudda et al., 2006) . When designing compounds V and VII, we focused once more on position 7, which is occupied by a Pro residue in the BK molecule. We decided to substitute d-Phe 7 in Stewart's peptide with a structural isomer of proline, l-β 2 -iPro or its homologue, l-β 3 -hPro. As mentioned above, in the blood pressure test, analogue V was a weak B 2 agonist at low doses, exhibiting weak antagonism at higher doses, while compound VII possessed antagonistic properties much lower than that of the model compound. Peptides V and VII differ from one another by the presence of the proline derivatives with only slightly different structures (see Fig. 1 ). In our opinion, this minor structural difference may have a significant impact on bioactive conformations of the molecules and consequently may influence their interaction with B 2 receptors. These findings seem to support our previous results obtained for modification of position 7 of the BK analogues with the d-1-Nal and d-2-Nal residues (Prahl et al., 1997a) .
Our hypothesis that acylation of the N-terminus of BK antagonists with bulky groups regularly improves the antagonistic potency in the blood pressure test, substantiated by our earlier results (Lammek, 1994; Lammek et al., 1990; , does not appear to be valid for each pair of the analogues. In this study, the acylated compounds, with one exception, were less potent than the non-acylated ones (analogues I and II, III and IV, V and VI). In the case of the rat uterus test, acylation resulted in either retention (peptides V and VI) or suppression of the agonistic activity (peptides I and II, VII and VIII), or enhancement of antagonistic potency (peptides III and IV).
Two of the new analogues (III and IV) are potent B 2 antagonists in both assays. However, other tested peptides which showed a strong (I and II) or moderate (VIII) antagonistic potency in the blood pressure test turned out to be agonists in the rat uterus test. This would support the idea of the presence of different types of BK receptor in the rat uterus and blood vessels.
The question of the existence of more than two BK receptor subtypes within a single species remains a great issue in the BK receptor field. The possibility of interspecies differences has clearly been shown because predicted amino-acid sequences of cloned receptors in different species vary. The most conclusive experimental evidence for species-related differences in BK receptors relates to studies with B 2 receptor antagonists. For peptide antagonists, affinities are generally greater in preparations taken from the rat and rabbit than in that taken from the guinea pig; contrary is the case for the non-peptide antagonist WIN64338 (Hall & Morton, 1997) . Indeed, an analysis of these and other data has led one group to propose the existence of B 2A (rabbit, dog, and possibly man) and B 2B (guinea pig, hamster, rat) receptors (Regoli et al., 1994) . The strongest evidence for a B 3 receptor comes from the work of Farmer and colleagues who reported that various B 1 and B 2 receptor antagonists had very weak affinities and did not displace specific BK binding in the guinea-pig trachea (Farmer et al., 1989) . However, subsequent studies by this group and other ones gave conflicting results and no clear-cut conclusions can be made regarding the existence of B 3 receptors (Hall & Morton, 1997) . It should be noted, however, that up to the present there is no evidence for more than one gene for B 2 receptor within a single species and B 2 receptor gene knockout mouse has lost all responses to exogenous BK (Borkowski et al., 1995) . Alternative splicing of a single gene transcript cannot also be ruled out. Some of the pharmacological discrepancies observed with BK and its antagonists may be explained by the interaction with orphan G-proteincoupled receptors for which ligands are not known. Recently, Boels and Schaller (2003) described the discovery and tissue-specific expression of a novel human gene encoding GPCR 100 (GPR100). This orphan receptor is present in locations where kinins act (such as heart, skeletal muscle, some endocrine glands and brain areas) and is claimed to be a new high-affinity receptor for BK and kallidin.
